U.S. Markets closed

Theralase Technologies Inc. (TLT.V)

TSXV - TSXV Delayed Price. Currency in CAD
Add to watchlist
0.465-0.02 (-4.12%)
At close: 3:59PM EDT
People also watch
Interactive chart
Previous Close0.485
Bid0.465 x
Ask0.475 x
Day's Range0.460 - 0.540
52 Week Range0.180 - 0.540
Avg. Volume505,656
Market Cap57.76M
PE Ratio (TTM)-10.33
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Zacks Small Cap Researchlast year

    TLT.V: Q1 2016 Financial Results; Revenue Misses Estimates But Growth Is Stronger Than Q1 2015

    Revenue came in at ~$400,000 but widely missed our estimate by ~50%.  The domestic market (Canada) revenue decreased ~50% as compared to the same period in 2015 offsetting more than ~50% bump in international regions.  The U.S. revenue jumped by 1700% from Q1 2015.  Theralase is focused on training its marketing team to grow its U.S. revenues as well as international revenues through exclusive distribution agreements.

  • Theralase Technologies, Inc. Earnings Q2, 2015
    Capital Cube2 years ago

    Theralase Technologies, Inc. Earnings Q2, 2015

    Theralase Technologies, Inc. reports preliminary financial results for the quarter ended June 30, 2015.We analyze the earnings along side the following peers of Theralase Technologies Inc. – Pyng Medical Corp., Verisante Technology, Inc., Medx Health Corp. and CRH Medical Corporation (PYT-CA, VRS-CA, MDX-CA and CRH-CA) that have also reported for this period.HighlightsSummary numbers: Revenues of […] (Read more...) The post Theralase Technologies, Inc. Earnings Q2, 2015 appeared first on CapitalCube.

  • Zacks Small Cap Research2 years ago

    TLT.V : A Slow Second Quarter And Pending Health Canada Approval Keeps Business Plans Chugging Along Slowly For Theralase.

    For the six month period ending June 30, 2015 sales revenues increased by 11% in Canada while in the U.S. it decreased by 54% and international revenue decreased by 89% as compared to 1H 2014. Management  intends to maintain sales of the TLC-1000 and TLC-900 devices in the Canadian market for the first three quarters of 2015 until they commence launch of their next generation device, the TLC-2000, pending Health Canada approval. The increased spend in SG&A are due to expenses related to investor relations activities, legal fees for additional trademark and intellectual property patents in both its therapeutic laser and anti-cancer divisions, and granting and vesting of stock options to employees of the company.